Adenoviral-based vaccine promotes neoantigen-specific CD8+ T cell stemness and tumor rejection.
D'Alise AM, Brasu N, De Intinis C, Leoni G, Russo V, Langone F, Baev D, Micarelli E, Petiti L, Picelli S, Fakih M, Le DT, Overman MJ, Shields AF, Pedersen KS, Shah MA, Mukherjee S, Faivre T, Delaite P, Scarselli E, Pace L.
D'Alise AM, et al. Among authors: petiti l.
Sci Transl Med. 2022 Aug 10;14(657):eabo7604. doi: 10.1126/scitranslmed.abo7604. Epub 2022 Aug 10.
Sci Transl Med. 2022.
PMID: 35947675
Free PMC article.